NEW YORK – Sysmex said Tuesday that it has expanded its strategic partnership with Qiagen in the area of genetic testing. The firms have also agreed that a Qiagen-developed molecular assay will be used at Sysmex's global laboratory network to support clinical trials by pharma companies and research institutions.
Qiagen of Germany and Japan-based Sysmex began their partnership in 2013 and formed an alliance in 2021 to develop and commercialize companion diagnostics using Sysmex's Plasma-Safe-SeqS next-generation sequencing platform, which is designed to reduce NGS reading errors by tagging amplified DNA. Under their new agreement, the firms are deepening their collaboration in genetic testing to include R&D, production, clinical development, and sales and marketing of testing products.
"As part of the newly expanded collaboration, both companies will further combine their respective products and strengths in genetic testing to deliver high-value products to their global customers," Sysmex said in a statement.
The firms previously announced that their partnership would support collaborations with pharmaceutical companies that are developing cancer therapies and the early adoption of ultra-sensitive liquid biopsy companion diagnostics.